AAMU
CRVS icon

Amundi Asset Management US’s Corvus Pharmaceuticals CRVS Stock Holding History

Amundi Asset Management US’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,600
Closed -$74K – 1611
2018
Q3 		$74K Hold
8,600
– – ﹤0.01% 1544
2018
Q2 		$94K Buy
+8,600
New +$96K ﹤0.01% 1469

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Amundi Asset Management US's CRVS Position: Q4 2018 in Review

Amundi Asset Management US sold out of Corvus Pharmaceuticals (CRVS) in Q4 2018, closing a stake of 8,600 shares — an estimated $74K sold.

Amundi Asset Management US first reported a position in CRVS in Q2 2018 and held it in 2 quarters. The position peaked at $94K in Q2 2018. 61 funds tracked by Wall St. Rank hold CRVS as of Q4 2018.

  • Amundi Asset Management US reported no remaining Corvus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 8,600 Corvus Pharmaceuticals shares in Q4 2018, an estimated $74K.
  • Amundi Asset Management US first reported a position in Corvus Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Amundi Asset Management US's Corvus Pharmaceuticals position peaked at $94K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.